Nature Reviews Cancer contents December 2014 Volume 14 Number 12 pp763-829

If you are unable to see the message below, click here to view.

Advertisement
AACR Annual Meeting 2015 Join the American Association for Cancer Research April 18-22 in Philadelphia, PA, for the most comprehensive cancer research meeting in the world. The AACR Annual Meeting 2015 will highlight the latest, most exciting discoveries in every area of cancer research and will provide a unique opportunity for investigators from all over the world to meet, interact, and share their insights. For more information, visit www.AACR.org/AACR2015
TABLE OF CONTENTS
December 2014 Volume 14 Number 12
Impact Factor 37.912 *	In this issue Research Highlights Reviews Perspectives Also this month  Featured article: The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer Douglas K. Graham, Deborah DeRyckere, Kurtis D. Davies & H. Shelton Earp
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Tumour evolution: Clonal ancestry in lung cancer p763 | doi:10.1038/nrc3867 Two papers describe the evolution and heterogeneity of non-small-cell lung cancers by carrying out sequencing of samples from multiple tumour regions, with interesting conclusions and raising challenges for the future. PDF Microenvironment: Small containers, important cargo p764 | doi:10.1038/nrc3864 Two papers have revealed new roles of exosomes in cancer progression: as mediators of therapeutic resistance signals from the stroma and as microRNA generators. PDF Colorectal cancer: Elongation is essential p764 | doi:10.1038/nrc3865 Faller et al. have shown that intestinal cells lacking APC require mTOR complex 1 (mTORC1) signalling for tumour formation, but that it is translation elongation controlled by mTORC1 (and not translation initiation) that is important in these cells. PDF Microenvironment: The new midfielders in the tumour microenvironment p765 | doi:10.1038/nrc3861 Broz et al. identify a rare intratumoral CD103+ dendritic cell population that stimulates cytotoxic T cells. PDF Signalling: Uncovering new functions of PI3K mutations p766 | doi:10.1038/nrc3863 Cheung et al. show that the protein encoded by a common mutation in PIK3R1 (the p85α subunit of PI3K) has neomorphic functions, including nuclear localization and the activation of ERK and JNK signalling, which can promote tumour cell proliferation and survival. Furthermore, tumours expressing this mutation are sensitive to MEK and JNK inhibitors. PDF Tumour immunology: Anticancer drugs copy bugs p766 | doi:10.1038/nrc3866 The induction of a type I interferon response in cancer cells is linked to the efficacy of certain chemotherapies. PDF IN BRIEF Immunotherapy: A lethal storm | Leukaemia: Explaining gender bias | Tumour suppressors: Take it up a Notch | Therapeutic resistance: Blocking the gatekeeper | Cell signalling: Migration fizzles out | Immunotherapy: CAR T cell distribution centres | Therapy: Caution for targeting the microenvironment | Signalling: Intrinsic intrigue PDF Cancer JOBS of the week Postdoct Researcher Positions in Molecular Cancer Biology University of Pennsylvania Postdoctoral Position in Cancer Systems Biology. Centre for Systems Medicine. RCSI Royal College of Surgeons in Ireland Faculty - Adolescent and Young Adult Cancer Research Case Western Reserve University Cancer Biologist Wake Forest Baptist Medical Center Cancer Biology / Oncology Tenure-track Faculty Position University of Pennsylvania, School of Veterinary Medicine More Science jobs from Cancer EVENT Advanced Breast Cancer Third International Consensus Conference (ABC3) 05.11.15 Lisbon, Portugal More science events from
REVIEWS		Top
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer Douglas K. Graham, Deborah DeRyckere, Kurtis D. Davies & H. Shelton Earp p769 | doi:10.1038/nrc3847 The TYRO3, AXL and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are overexpressed in tumour cells, promoting cell survival and chemoresistance. These RTKs also function in normal innate immune cells to promote an immunosuppressive tumour microenvironment. Thus, TAM RTKs are implicated as dual therapeutic targets in cancer. Abstract | Full Text | PDF | Supplementary information
Hypermutation in human cancer genomes: footprints and mechanisms Steven A. Roberts & Dmitry A. Gordenin p786 | doi:10.1038/nrc3816 Recent analyses of cancer genomes have revealed the occurrence of mutation patterns, which indicate their source. This Review discusses what we have learned, and what is yet to learn, from these data and how our current understanding of cancer mutations fits into our understanding of tumorigenesis and tumour progression. Abstract | Full Text | PDF
Aryl hydrocarbon receptor ligands in cancer: friend and foe Iain A. Murray, Andrew D. Patterson & Gary H. Perdew p801 | doi:10.1038/nrc3846 The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known for mediating the toxicity and tumour-promoting properties of dioxin. AHR levels are increased with constitutive nuclear localization in many tumours. How might AHR facilitate tumour progression, and can it be therapeutically modulated? Abstract | Full Text | PDF
PERSPECTIVES		Top
SCIENCE AND SOCIETY Bringing cancer care to the poor: experiences from Rwanda Lawrence N. Shulman,, Tharcisse Mpunga, Neo Tapela, Claire M. Wagner, Temidayo Fadelu & Agnes Binagwaho p815 | doi:10.1038/nrc3848 The knowledge and tools to effectively treat many cancer patients exist in developed countries but are unavailable to many who live in the developing world. This Science and Society article uses the example of Rwanda's expanding national cancer programme to discuss how cancer care can be brought to low-income countries that are considerably resource-constrained. Abstract | Full Text | PDF
SCIENCE AND SOCIETY Cancer screening and prevention in low-resource settings Aditi Shastri & Surendra Srinivas Shastri p822 | doi:10.1038/nrc3859 This Science and Society article outlines the burden of preventable cancers in selected less-developed-region countries (LDCs) and discusses evidence on cost-effective and widely implementable prevention and screening strategies. As LDCs typically have poor resources to treat cancers, the authors argue that investment in sustainable cancer prevention and screening strategies would be the best option to reduce cancer-related mortality in most LDCs. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.